Identifying interpretable gene-biomarker associations with functionally informed kernel-based tests in 190,000 exomes

Here we present an exome-wide rare genetic variant association study for 30 blood biomarkers in 191,971 individuals in the UK Biobank. We compare gene-based association tests for separate functional variant categories to increase interpretability and identify 193 significant gene-biomarker associations. Genes associated with biomarkers were ~4.5-fold enriched for conferring Mendelian disorders. In addition to performing weighted gene-based variant collapsing tests, we design and apply variant-category-specific kernel-based tests that integrate quantitative functional variant effect predictions for missense variants, splicing and the binding of RNA-binding proteins. For these tests, we present a computationally efficient combination of the likelihood-ratio and score tests that found 36% more associations than the score test alone while also controlling the type-1 error. Kernel-based tests identified 13% more associations than their gene-based collapsing counterparts and had advantages in the presence of gain of function missense variants. We introduce local collapsing by amino acid position for missense variants and use it to interpret associations and identify potential novel gain of function variants in PIEZO1. Our results show the benefits of investigating different functional mechanisms when performing rare-variant association tests, and demonstrate pervasive rare-variant contribution to biomarker variability.
multiple testing and low statistical power due to low allele frequencies[19]. For these reasons, variants in RVAS are typically grouped into sets that correspond to functional units, such as genes, before association testing[14–16]. Not only does this strategy aggregate signal and thereby increase statistical power, but it also lessens the burden of multiple testing. Burden tests, for example, collapse variants within genes into a single variable prior to association testing, i.e., perform gene-based variant collapsing[16]. Alternatively, kernel-based tests aggregate groups of variants into a so-called kernel-matrix that is tested using a score test[17] or the likelihood-ratio test (LRT)[18] without the need for collapsing. Among these, the LRT has higher statistical power when effect sizes are large, but is computationally more expensive[19,20].

While gene-based variant collapsing performs best in the presence of many causal variants with effect sizes that point in the same direction (e.g., increasing risk for disease), kernel-based tests have advantages in cases of opposing effects and fewer causal variants[16]. To increase the fraction of causal variants, exome-wide RVAS that use variant collapsing have defined qualifying variants based on annotations such as allele frequencies or variant effect predictions and excluded all other observed variants from the association tests[16,19]. These studies have mostly focused on non-synonymous variants, where software tools identify protein-truncating variants and distinguish between benign and potentially deleterious missense variants[19–20].

Here, we perform an extensive RVAS using exome sequencing data from the UK Biobank[21]. For approximately 190,000 individuals, 30 quantitative biomarkers provide objectively quantifiable measures related to the health status of individuals[22], making them attractive phenotypes for genomewide association studies[23]. We go beyond the collapsing tests for coding variants described above and explore the use of kernel-based association tests and deep learning-derived variant effect predictions for gene-regulatory variants, namely for splicing[24] and the binding of RNA-binding proteins (RBPs)[25].

Specifically, we use quantitative functional variant effect predictions to group and weigh variants in gene-based association tests and increase interpretability. The greater flexibility of kernel-based tests allowed us to design variant category-specific tests and combine collapsing and non-collapsing approaches in the same tests. For kernel-based tests, we show that a computationally efficient combination of the score test and the restricted likelihood-ratio test (RLRT) can identify 36% more significant associations compared to the score test alone. We find 193 significant gene-biomarker associations in total, the majority of which confirm associations previously reported to GWAS databases (87%)[26].

We find that including participants from diverse ancestries identifies 14% more associations than limiting to participants with strict inferred European genetic ancestry, while increasing the sample size by 17%. Associations with biomarkers frequently occurred in genes linked to Mendelian disorders, and comparisons to other association studies confirmed their plausible disease relevance. Finally, we interpret associations that were only found for specific functional variant categories or associations for which weighted gene-based variant collapsing and kernel-based tests gave vastly different results. This provided additional biological insights and highlighted the benefits of a diverse testing strategy for RVAS.

## Results

### Data description and workflow

We performed an RVAS of 30 quantitative serum biomarkers in UK Biobank 200k WES release[21]. These biomarkers contain established disease risk factors, diagnostic markers, and markers for phenotypes otherwise not well assessed in the UK Biobank cohort. They can roughly be grouped into cardiovascular, bone and joint, liver, renal, and diabetes markers (Table 1). After removing related individuals and restricting the analysis to those with no missing covariates, 191,971 participants with diverse genetic ancestry remained. About 15,702,718 rare (MAF < 0.1%) variants were observed in this subset and passed participants with diverse genetic ancestry remained. About 15,702,718 rare (MAF < 0.1%) variants were observed in this subset and passed quality criteria, including pruning variants with large deviations from the observed European MAF in other ancessries (Methods). The median sample size for the biomarkers was 181,784 and ranged from 15,997 (Rheumatoid factor) to 182,742 (Alkaline phosphatase). About 191,260 participants had at least one measured biomarker.

We used functional variant effect predictions to group and weigh variants and performed functionally informed gene-based association tests. Specifically, we chose to investigate strict protein loss of function variants (pLOF, e.g., frame shift or protein-truncating variants), missense variants, splice-altering variants, and variants predicted to change the binding of RNA-binding proteins (Fig. 1, Methods), the latter two originating from deep learning models[24,25].

We treated these categories separately during association testing to increase interpretability, resulting in multiple tests per gene, which we refer to as separate models. Specifically, we adapted either kernel-based tests, weighted gene-based variant collapsing, or both types of association test depending on the variant effect category (Methods). Tests were performed using a combination of score tests and restricted likelihood-ratio tests. We make variant effect predictions for all variants in the UK Biobank 200k exome release available (https://

### Table 1 | UK Biobank blood biomarkers analyzed in this study

| category          | biomarker                      | short | N     | sign. genes |
|-------------------|--------------------------------|-------|-------|-------------|
| bone and joint    | Alkaline phosphatase           | ALP   | 182,742| 10          |
| bone and joint    | Calcium                        |       | 168,054| 3           |
| bone and joint    | Rheumatoid factor              |       | 15,997 | 0           |
| bone and joint    | Vitamin D                      |       | 174,473| 4           |
| cardiovascular    | Apolipoprotein A               | ApoA  | 167,050| 18          |
| cardiovascular    | Apolipoprotein B               | ApoB  | 181,808| 6           |
| cardiovascular    | C-reactive protein             | CRP   | 182,320| 3           |
| cardiovascular    | Cholesterol                    |       | 182,735| 9           |
| cardiovascular    | HDL cholesterol                | HDL   | 168,043| 20          |
| cardiovascular    | LDL direct                     | LDL   | 182,420| 6           |
| cardiovascular    | Lipoprotein A                  |       | 146,249| 13          |
| cardiovascular    | Triglycerides                  | TG    | 182,587| 12          |
| diabetes          | Glucose                        |       | 167,916| 3           |
| diabetes          | Glycated hemoglobin            | HbA1c | 182,494| 9           |
| hormonal          | IGF-1                          |       | 181,759| 7           |
| hormonal          | Oestradiol                     |       | 30,343 | 0           |
| hormonal          | SHBG                           |       | 166,521| 6           |
| hormonal          | Testosterone                   |       | 165,211| 1           |
| liver             | Alanine aminotransferase       | ALT   | 182,675| 5           |
| liver             | Albumin                        |       | 168,139| 4           |
| liver             | Aspartate aminotransferase     | AST   | 182,096| 2           |
| liver             | Direct bilirubin               |       | 154,963| 6           |
| liver             | Gamma glutamyltransferase      | GGT   | 182,655| 7           |
| liver             | Total bilirubin                |       | 181,998| 8           |
| renal             | Creatinine                     |       | 182,639| 7           |
| renal             | Cystatin C                     |       | 182,720| 7           |
| renal             | Phosphate                      |       | 187,808| 3           |
| renal             | Total protein                  |       | 187,931| 5           |
| renal             | Urate                          |       | 182,538| 8           |
| renal             | Urea                           |       | 182,612| 1           |

Biomarker categories, biomarker names, their abbreviations used in the text (short), sample size (i.e., participants non-missing phenotype and complete covariates), N and number of distinct genes significantly associated with each biomarker (sign. genes) after multiple testing correction (FWER ≤ 0.05).
We identified 75 significant associations with gene-based variant collapsing in 44 distinct genes, whereas kernel-based tests identified 88 significant associations in 51 genes. As our definition of pLOF variants included variants that directly hit annotated splice donor/acceptor sites, there was a considerable overlap of 95,842 variants between these annotations (21% of all pLOF variants). We therefore expected (and found) large overlaps (69, 74%) in the significant associations for pLOF and splice variants.

**RBP-binding.** Splicing is only one of several eukaryotic post-transcriptional regulatory mechanisms mediated by interactions of RNA-binding proteins (RBPs) with their target RNAs. As the UK Biobank WES data also contain variants in non-protein-coding parts of mRNAs, namely in introns (41.43%) and UTRs (11.32%), we reasoned that we might be able to identify variants with regulatory effects mediated by differential binding of RBPs. Specifically, we investigated if changes in the binding of RBPs predicted by DeepRIPe23 could be associated with biomarker levels. The six RBPs QKI, MBNL1, TARDBP, ELAVL1, KHDRBS1, and HNRNPD were selected based on their binding predictions by DeepRIPe in 17,394 genes, with a median of 12 variants per gene (Methods).

As we expected a low number of causal variants and potentially opposing effect sizes, we only performed kernel-based association tests and identified nine significant associations in nine distinct genes.

**Integrative analysis overview**

Merging the results from all models yielded a total of 193 associations originating from 117 distinct genes (Supplementary Data 1, 212 associations if counting genes with shared exons separately). We found at least one significant association for all but two biomarkers (oestradiol and rheumatoid factor) (Fig. 2 and Supplementary Figs. 1–3). For the majority of associations (174; 82%), tests combining missense and protein LOF variants gave the smallest p values.

We calculated the genomic inflation factor \( \hat{\lambda}_{GC} \) across all tests that were performed genome-wide, and did not find evidence of inflated type I error levels (Supplementary Fig. 8 and Supplementary Data 5). \( \hat{\lambda}_{GC} \) ranged from 0.94 to 1.06 for gene-based variant collapsing tests (median = 0.97) and from 0.92 to 1.08 for kernel-based tests (median = 1.01). Of the 117 distinct genes, 43 (37%) were associated with more than one biomarker, and a few genes had five or more significant associations: ANGPTL3, APOB, JAK2, GIGYF1, and G6PC. Many of the genes we found to be associated with biomarkers had either been implicated in diseases related to those biomarkers (e.g., LRP2 with renal markers25) or are mechanistically related to the biomarkers themselves (e.g., cystatin C with its own gene, CST7).

80% of genes (±5kb) contained single variants associated with the same biomarkers identified by a study using imputed genotypes and a larger sample size on the same data25. Yet, 97% of gene-phenotype associations remained significant after conditioning on the most significant variants identified by that study (considering variants ±500 kb around the gene start positions). We therefore conclude that most associations we observed are largely independent of the signals captured by array-based genotypes of (mostly) common variants.

**Including all ancestries increases the power for biomarker traits**

We repeated our analysis restricting to 164,148 individuals of strict inferred European ancestry (Methods). While 75 associations were significant in both analyses, 37 were only identified in the analysis with all ancestries (AA) and 11 were only significant in the analysis with EUR individuals (Fig. 3 and Supplementary Data 3). The majority of hits significant in one analysis but not in the other were close to the significance threshold. Outliers such as the associations of ALD16A1 with
Urate could all be explained by hard thresholds for variant inclusion and strong signals from single variants. Both the type of association test and variant category that produced the lowest gene-trait \( p \) values were largely consistent in both analyses (Fig. 3).

**Clinical relevance of biomarker associations**

Genes identified by biomarker associations were highly enriched for those involved in Mendelian disorders (odds ratio 4.47, \( p \) value \( 3.08 \times 10^{-16} \), one-sided Fisher’s exact test), as determined by querying the Online Mendelian Inheritance in Man database (OMIM, https://omim.org). Seventy-four out of 125 (59.2%) distinct (i.e., non-overlapping) genes identified had at least one OMIM entry. Our results show that changes at the biomarker level are detectable even in the 27 genes for which only recessive disorders were listed.

We further examined whether rare variants in these genes were associated with binary or continuous traits at larger sample sizes by comparing with two studies published at the time of writing15,16 (Supplementary Data 4). Twenty-one out of 125 genes associated with biomarkers were also associated with one or more binary traits, whereas 14 genes were associated with non-hematological quantitative traits in either study (Table 2).

Often such cases could be placed in a plausible causal context. For example, we found variants in SLC22A12, ABCG2, and ALDH1H6A1 to be associated with increased levels of urate, a causal factor for gout, which they were also associated with. Another example are genes associated with the growth hormone IGF-1 (IGFALS, GHI, GHRH, and PAPPA2), which are also associated with anthropometric traits (e.g., sitting height). We identified patterns of biomarker associations for GIGYF1 consistent with Type II diabetes (T2D), and an association with T2D was confirmed at larger sample sizes31,34 and other independent studies30,32. Six out of seven biomarker associations for JAK2 were only identified by kernel-based tests, and the gain of function variant driving these associations (V617F or rs7737549334) was also associated with myeloproliferative neoplasms. In other cases, trait-biomarker relationships were not readily apparent, such as the association of variants in SYM2 with lower levels of \( \gamma \)-glutamyltransferase and increased risk of hearing loss.

Separating variant effect categories during association testing and comparing kernel-based to gene-based collapsing tests allowed us to further interpret our results, as illustrated with several examples below.

**Combining variant annotations yields six associations for G6PC**

We found five associations for G6PC, three of which were only found when combining protein LOF and missense variants with gene-based variant collapsing tests (alkaline phosphatase, SHBG, and urate). Variants in G6PC cause Glucose-6-phosphatase deficiency type Ia35,36, an autosomal recessive disease categorized by growth retardation, enlarged kidneys and liver, low blood glucose, high blood lipid, and uric acid levels. Consistent with signs of inflammation and impaired kidney and liver function, we found elevated levels of alkaline phosphatase (\( p = 1.15 \times 10^{-7} \)), \( \gamma \)-glutamyltransferase (\( p = 2.64 \times 10^{-16} \)), and C-reactive protein (\( p = 1.62 \times 10^{-15} \)) in individuals with predicted high-risk missense or pLOF mutations in G6PC. We further identified a significant association with decreased levels of sex hormone-binding globulin (SHBG, \( p = 2.88 \times 10^{-7} \)), which is primarily produced in the liver37. All \( p \) values above are those given by gene-based weighted variant collapsing tests combining missense and pLOF variants, which gave the lowest \( p \) value for all these associations.
phosphatase deficiency type Ia is a rare recessive disease, our findings show that altered biomarker levels indicative of mild symptoms are detectable in heterozygous carriers of missense and LOF variants in the GfPC gene, a pattern which was consistent for many of the identified genes.

**Novel potential gain of function variants in PIEZO**

Our testing strategy allowed us to identify genes in which specific variant categories might play an important role. One such example was PIEZO1, a mechanosensitive cation channel, which we found associated with the diabetes marker HbA1c.

For weight-based gene-based variant collapsing tests, we found a significant negative association of missense variants with HbA1c (p = 7.47 × 10⁻²⁹), while the test for pLOF variants was not significant (p = 0.89, 609 carriers). By far the lowest p value for this gene was given by the kernel-based test for missense variants (p = 2.8 × 10⁻⁴⁰). The large differences between variant categories and types of association test led us to closer investigate the 858 predicted high-impact missense variants in 7412 individuals for this gene.

We performed single-variant score tests and identified multiple missense variants with strong negative associations with HbA1c (Table 3). One of these variants, 16:88719665:C:A or T2127M (rs58776991) is a gain of function variant that slows down inactivation kinetics of PIEZO1 in patients with dehydrated hereditary stomatocytosis (a disorder of red blood cells), together with other gain of function variants. Decreased levels of HbA1c had previously been observed in individuals with red blood cell disorders.

We therefore hypothesized that the other highly significant variants could also potentially be gain of function variants. We grouped the missense variants within PIEZO1 by the amino acid positions they affected and performed local variant collapsing. This allowed us to identify other positions in PIEZO1 (e.g., 2110R or 2474V) that are potentially sensitive to gain of function mutations (Table 3 and Fig. 4).

When comparing the results of our all-ancestry analysis, which includes ancestry-based variant pruning, to a version which did not, we came across another missense variant (L2277M, 16:88716656:G:T), which was much more common in individuals with inferred South Asian ancestry (SAS, MAF = 3.45%) than European ancestry (MAF = 0.006%, p = 0, two-sided Fisher’s exact test), and strongly associated with decreased levels of HbA1c (β = 0.71 ± 0.06 s.d., p = 1.16 × 10⁻²⁹, score test restricted to individuals of inferred SAS ancestry, Supplementary Fig. 4). L2277M has been linked to dehydrated hereditary stomatocytosis. This association remained significant when conditioning on a recently identified nearby non-coding variant (16:88784993:C:G, p = 9.1 × 10⁻¹⁵), yet, not the other way around (p = 0.55). 16:88784993:C:G could therefore be tagging signal from the potentially causal gain of function variant L2277M. We were able to replicate this association in individuals with extended EUR ancestry (p = 2.73 × 10⁻⁸, score test, Methods).

Consistent with the role of red blood cell disorders, we also found associations of RHAG (Rh Associated Glycoprotein) and SPTA1 with decreased levels of HbA1c. Mutations in RHAG cause overhydrated hereditary stomatocytosis, while SPTA1 mutations cause hereditary elliptocytosis.
While it has been suggested that PIEZO1 stimulates insulin release\(^\text{48}\), the decreased levels of HbA1c we observed in individuals with PIEZO1-variants are more likely explained by (perhaps subclinical) forms of stomatocytosis or other abnormalities in red blood cells resulting from increased membrane permeability, i.e., a gain of function\(^\text{49}\).

**Position-specific association of ABCA1 variants with inflammation marker CRP**

We found four significant associations of ABCA1 with biomarker levels. Three of these, namely the associations with Apolipoprotein A, HDL cholesterol, and cholesterol, are directly related to its role as an ATP-dependent transporter of cholesterol\(^\text{50}\). In line with previous findings, in our gene-based variant collapsing analysis we found both pLOF and high-impact missense variants to be strongly associated with CRP (Fig. 4). The two variants carried most of the signal in this gene with single-variant \(p\) values of \(6.3 \times 10^{-8}\) for W590L (A allele, 54 carriers) and \(8.09 \times 10^{-8}\) for W590S (G allele, 12 carriers, score test).

The W590S-variant leads to reduced cholesterol and phospholipid efflux, while retaining expression and ability to bind APOAI\(^\text{52,53}\). The other and more common variant, W590L, has been observed\(^\text{54,55}\), but to our knowledge, not experimentally evaluated.

The binding of APOAI to ABCA1 activates anti-inflammatory pathways via JAK2 and STAT3 in macrophages\(^\text{56}\). Because W590S has been shown to slow down dissociation of bond APOAI\(^\text{52}\), this provides a plausible causal mechanism for the reduced levels of CRP we observe in carriers of the W590S-variant. We hypothesize that W590L might act through the same mechanism. This property could set these variants apart from other missense variants in ABCA1, which have been reported to abolish the binding of APOAI\(^\text{52}\). ABCA1 could therefore be a gene in which some variants elicit both a gain of function (slower dissociation of APOAI) and a loss of function (decreased cholesterol efflux) with distinct effects on different biomarkers.

**Unique associations identified by splice predictions**

In total, we identified six gene-biomarker associations exclusively when incorporating SpliceAI variant effect predictions, of which four

---

**Table 2 | Significant genes with non-hematological trait associations in other RVAS**

| category       | gene name | biomarker | analysis | \(p\) value | effect | test | \(N_\text{variant}\) | \(N_\text{carrier}\) | OMIM | traits (examples) |
|----------------|-----------|-----------|----------|-------------|--------|------|---------------------|---------------------|-------|------------------|
| bone and joint | HSPG2     | ALP       | AA       | 2.27e-19    | m      | K    | 1424                | 10,275              | r     | repair of conjunctiva |
| bone and joint | B4GALNT3  | ALP       | AA       | 3.91e-14    | m      | gbvc | 246                 | 2499                | height |                  |
| bone and joint | FLG       | Vitamin D | AA       | 1.54e-10    | p      | gbvc | 350                 | 2448                | d,r   | asthma, eczema     |
| cardiovascular | APO8      | LDL direct (+5) | AA | 9.69e-159    | m      | K    | 855                 | 3948                | d,r   | high cholesterol (diag.) |
| cardiovascular | PCSK9     | LDL direct (+2) | AA | 4.56e-88    | m      | gbvc | 186                 | 968                 | d     | high cholesterol (diag.) |
| cardiovascular | APOC3     | Triglycerides (+2) | AA | 2.18e-74    | m      | K    | 28                  | 297                 | m     | lipid-lowering med   |
| cardiovascular | LDLR      | LDL direct (+3) | AA | 2.29e-50    | m      | gbvc | 214                 | 1303                | d,r   | high cholesterol (diag.) |
| cardiovascular | PDE3B     | Triglycerides (+1) | AA | 7.66e-24    | m      | K    | 225                 | 1510                | height, mass |
| cardiovascular | JAK2      | LDL (+6)  | AA       | 5.22e-19    | m      | K    | 254                 | 1022                | m,s   | neoplasms           |
| cardiovascular | G6PC      | CRP (+4)  | AA       | 1.62e-13    | m      | gbvc | 85                  | 828                 | r     | arm fat free mass   |
| cardiovascular | TM6SF2    | Triglycerides (+2) | AA | 3.10e-13    | m      | gbvc | 85                  | 1392                | liver fat percentage |
| cardiovascular | SRSF2     | HDL       | EUR\(^*\) | 6.19e-09    | m      | K    | 10                  | 51                  | myeloid leukemia |
| diabetes       | PIEZO1    | HbA1c     | AA       | 5.59e-108   | m      | K    | 1,011               | 8021                | d,r   | vascice veins, height, mass |
| diabetes       | GCK       | HbA1c     | EUR\(^*\) | 1.36e-40    | m      | gbvc | 53                  | 144                 | d,r   | T2D, education score Engl. |
| diabetes       | GIGYF1    | HbA1c (+4) | AA | 1.14e-10   | p      | gbvc | 41                  | 68                  | T2D, ed | |
| diabetes       | HBB       | HbA1c     | AA       | 1.10e-09    | m      | K    | 33                  | 92                  | d,r   | thalassemia         |
| hormonal       | SHBG      | SHBG (+1) | AA       | 4.64e-227   | m      | K    | 105                 | 669                 | heel bone mineral density |
| hormonal       | IQFALS    | IGF-1     | AA       | 1.14e-78    | m      | K    | 242                 | 1900                | r     | height, mass        |
| hormonal       | GH1       | IGF-1     | AA       | 1.85e-10    | s      | gbvc | 49                  | 470                 | d,r   | height, mass        |
| hormonal       | GHRH      | IGF-1     | AA       | 2.07e-09    | m      | gbvc | 22                  | 117                 | height, mass |
| hormonal       | PAPPA2    | IGF-1     | AA       | 5.38e-09    | m      | gbvc | 268                 | 1208                | r     | height, mass        |
| liver          | UGT1A1    | Total bilirubin (+1) | AA | 2.90e-67   | m      | K    | 148                 | 864                 | m,r   | Gilbert’s syndrome |
| liver          | ABCB4     | ALT       | AA       | 2.30e-10    | m      | gbvc | 226                 | 1192                | d,r   | cholelithiasis      |
| liver          | SYNJ2     | GGT       | AA       | 1.55e-08    | m      | gbvc | 434                 | 3020                | hearing loss |
| renal          | SLC22A12  | Urate (+1) | AA | 0         | m      | gbvc | 151                 | 1044                | r     | gout               |
| renal          | ALDH1H6A1 | Urate     | EUR\(^*\) | 4.40e-23   | m      | K    | 266                 | 2060                | gout   |
| renal          | ABCG2     | Urate     | AA       | 2.19e-14   | m      | gbvc | 170                 | 1575                | m     | gout               |
| renal          | TNFRSF13B | Total protein | AA | 1.62e-12   | m      | gbvc | 76                  | 898                 | d,r   | interop. age when op. |
| renal          | ANKRD12   | Total protein | AA | 3.18e-11   | p      | gbvc | 53                  | 121                 | walking pace: slow |
| renal          | PKD1      | Creatinine | EUR\(^*\) | 2.77e-10 | m      | K    | 1,255               | 10,695              | d     | cystic kidney disease |

Table showing the most significant gene-biomarker associations (FWE \(p < 0.05\) for all genes that were also significantly associated with non-hematological traits (e.g., disease diagnoses or anthropometric traits) in ref. 15 or ref. 16 in either the all-ancestry analysis (AA) or the EUR-ancestry analysis (EUR). Only example traits are shown in column “traits”. The full data are available in Supplementary Data 4. The numbers in brackets indicate how many other biomarkers are associated with the same gene in our analysis. effect: the lead variant effect type (m: missense pLOF, p: pLOF, s: splice + pLOF). test: the test-type which gave the lowest \(p\) value. OMIM: If disorders are linked to the gene in OMIM, their inheritance patterns (d: dominant, m: missing, r: recessive, s: somatic). Associations marked with \(^*\) were not significant in the AA-analysis, see Supplementary Data 1 and 3 for details.
were only found using kernel-based association tests. Specifically, we found associations of variants in SLCA9S with ApoA and HDL cholesterol, NDUF88 with Aspartate aminotransferase, GH1 with IGF-1, ECE1 with Alkaline phosphatase, and KDM6B with SHBG.

Most of these associations were mainly caused by single variants. An exception was the known association of HbA1c (growth hormone 1) with IGF-1, one of the two hits in this subset also found by gene-based variant collapsing. The interpretation of single highly significant variants driving these associations could not necessarily be narrowed down to a single mechanism. For example, the predicted splice variant in the last exon responsible for the two significant associations of SLCA9S (16:67270978:G:A, 29 carriers, Fig. 5a) was also a missense variant (albeit with low to moderate predicted impact55).

### Table 3 | Potential PIEZO1 gain of function variants

| variant id | position | weight | variant | N_{variant} | variant \( p \) val. | \( \beta \) variant | \( \pm \) | position | \( p \) value | \( \beta \) position | \( \pm \) |
|------------|----------|--------|---------|-------------|-----------------|-------------------|-------|----------|----------------|-------------------|-------|
| 16:88736318:C:T | 463 | 0.98 | A/T | 109 | 1.52e-10 | -0.56 | 0.09 | 2.01e-10 | -0.56 | 0.09 |
| 16:88736317:G:A | 463 | 1.00 | A/V | 1 | 8.97e-01 | 0.12 | 0.92 | 2.01e-10 | -0.56 | 0.09 |
| 16:88734895:G:A | 610 | 0.68 | L/F | 63 | 4.82e-08 | -0.63 | 0.12 | 9.55e-08 | -0.71 | 0.13 |
| 16:88734884:A:C | 610 | 0.99 | L/R | 4 | 7.00e-01 | -0.18 | 0.46 | 9.55e-08 | -0.71 | 0.13 |
| 16:88731880:C:T | 1008 | 0.99 | G/R | 65 | 7.20e-14 | -0.85 | 0.11 | 4.30e-15 | -0.88 | 0.11 |
| 16:88731880:C:T | 1008 | 0.99 | G/R | 3 | 1.18e-02 | -1.33 | 0.53 | 4.30e-15 | -0.88 | 0.11 |
| 16:88726891:A:C | 1175 | 1.00 | F/V | 4 | 4.71e-08 | -2.50 | 0.46 | 4.71e-08 | -2.50 | 0.46 |
| 16:88726565:C:T | 1260 | 0.71 | V/I | 78 | 8.03e-08 | -0.56 | 0.10 | 2.65e-08 | -0.68 | 0.12 |
| 16:88726565:C:A | 1260 | 1.00 | V/F | 1 | 6.67e-02 | -1.68 | 0.92 | 2.65e-08 | -0.68 | 0.12 |
| 16:88721626:C:G | 1772 | 0.99 | R/P | 12 | 3.11e-05 | -1.10 | 0.26 | 1.61e-08 | -1.07 | 0.19 |
| 16:88721627:C:G | 1772 | 0.98 | R/G | 10 | 9.12e-04 | -0.96 | 0.29 | 1.61e-08 | -1.07 | 0.19 |
| 16:88721626:C:A | 1772 | 0.98 | R/L | 1 | 3.90e-02 | -1.89 | 0.92 | 1.61e-08 | -1.07 | 0.19 |
| 16:88721627:C:G | 1772 | 1.00 | R/C | 1 | 4.89e-01 | -0.63 | 0.92 | 1.61e-08 | -1.07 | 0.19 |
| 16:88721423:C:G | 1804 | 0.87 | G/A | 31 | 7.92e-11 | -1.07 | 0.16 | 7.92e-11 | -1.15 | 0.18 |
| 16:88719717:G:A | 2110 | 1.00 | R/W | 9 | 6.68e-18 | -2.63 | 0.31 | 5.28e-33 | -2.66 | 0.22 |
| 16:88719716:C:T | 2110 | 0.89 | R/Q | 9 | 1.03e-16 | -2.53 | 0.31 | 5.28e-33 | -2.66 | 0.22 |
| 16:88719665:C:T | 2127 | 1.00 | T/M | 22 | 1.16e-11 | -2.29 | 0.20 | 1.16e-11 | -2.29 | 0.20 |
| 16:88726234:T:C | 2365 | 0.81 | G/R | 9 | 3.74e-16 | -2.49 | 0.31 | 3.74e-16 | -2.76 | 0.34 |
| 16:88715751:C:T | 2474 | 0.99 | V/M | 101 | 3.77e-08 | -0.50 | 0.09 | 9.58e-09 | -0.52 | 0.09 |
| 16:88715751:C:G | 2474 | 0.88 | V/L | 2 | 2.99e-02 | -1.41 | 0.65 | 9.58e-09 | -0.52 | 0.09 |
| 16:88715751:C:G | 2474 | 0.88 | V/L | 1 | 8.00e-01 | -0.23 | 0.92 | 9.58e-09 | -0.52 | 0.09 |

Variants are grouped and ordered by amino acid position and single-variant \( p \) values. All variants with position \( p \) values below 10\(^{-16}\) are shown. weight: impact score; \( N_{variant} \): number of carriers; variant \( p \) val.: single-variant \( p \) value (score test); \( \beta \) variant: variant linear regression effect size (±standard error); position \( p \) value: \( p \) value when collapsing variants by position after weighting (score test); \( \beta \) position: position linear regression effect size after weighting and variant collapsing (±standard error). Positions relate to the ENST00000301015 transcript.

**Fig. 4 | Local collapsing of missense variants.** Dosage box plots showing the alternative amino acid counts (x-axis) against the covariate-adjusted quantile-transformed phenotypes (y-axis). Collapsing variants by amino acid position within significant genes (FWER ≤ 0.05) identifies negative associations of PIEZO1 R1772-variants with HbA1c (\( p = 1.61×10^{-3} \)), ABCA1 W590-variants with C-reactive protein (\( p = 3.43×10^{-3} \)), and HNF4A R136-variants with Apolipoprotein A (\( p = 1.2×10^{-3} \)). \( p \) values were derived using the score test after weighting and collapsing variants (Methods). Collapsing together with ClinVar variants with reported conditions (marked with \( * \)) helps place novel variants into disease context. For all three associations, collapsed \( p \) values were lower than those of the single variants. Center lines denote the medians. The lower and upper hinges indicate 25th and 75th percentiles, whiskers extend to the largest/lowest values no further than 1.5 × IQR away from the upper/lower hinges and black points denote outliers. Maxima and minima, from left to right: -5.33 to 4.95, -4.05 to 5.69, and -4.7 to 4.5.
were found associated with (ALPL and SHBG), therefore we could not exclude transcriptional cis-regulatory effects as the cause of these associations.

Associations identified by RBP-binding predictions

Out of the nine significant associations we identified using DeepRiPe variant effect predictions, the associations of ANGPTL3 with Triglycerides, and AGPAT4, PLG, and LPA with Lipoprotein A had also been found using other models. The extreme heritability of Lipoprotein A, which is largely due to variation in the LPA gene\(^58,59\), makes it hard to interpret the associations for the lead genes LPA, AGPAT4, and PLG, that all lie within a megabase distance to LPA. The association we observed for ANGPTL3 was largely driven by a single intronic variant (1:62598067:T:C, Fig. 5), which was predicted to increase the binding probability of QKI. The same variant on the opposite strand was also responsible for the association of DOCK7 with triglycerides. However, we determined that ANGPTL3 was more likely the causal gene, given the associations of ANGPTL3 with triglycerides we had independently found with other variant categories and the close proximity of an ANGPTL3 exon.

We further investigated this variant by assessing the binding probabilities of RBPs beyond the six RBPs in focus here that are predicted only a weak upstream donor loss (0.02) for this variant, which was well below the threshold of 0.1 we used to identify splice-altering variants, but indicative of the same trend.

The remaining five associations exclusively identified by association tests incorporating RBP-binding predictions were those of ATG16L1 with total bilirubin, SOD2 with Lipoprotein A, SLC39A4 with Alanine aminotransferase and SHARPIN with Alanine aminotransferase.

Both SHARPIN and SLC39A4 lie within half a megabase of the Alanine aminotransferase gene (GPT), therefore we could not exclude potential transcriptional cis-regulatory effects as the true cause for these associations. Furthermore, single variants carried most of the signal for both genes.

Common intronic variants of ATG16L1 were previously found to be associated with Crohn's disease, inflammatory bowel disease\(^61,62\), and increased bilirubin levels\(^23,63,64\). However, the association remained significant after conditioning on the intronic top variant from a previous study\(^5\).

Combined likelihood-ratio and score tests (sLRT)

In order to benefit from both the speed of the score test\(^8\) and the higher power of the LRT in the presence of large effect sizes\(^11,12\), we investigated the use of a combination of these tests, which we call the sLRT (score-LRT). The sLRT is a likelihood-ratio test that is performed only when initial score tests reach nominal significance at a given cutoff \(t\). If this threshold is not reached, it returns the score test \(p\) value. Throughout our analysis, we used \(t = 0.1\) and found that it was unlikely that a larger threshold would have identified many more associations (Supplementary Fig. 6). As the run time is dominated by the cost of computing the LRT, this test can achieve a computational speedup factor of roughly 1/10 over the LRT under the null hypothesis.

We found that the sLRT was able to identify more significant associations than the score test for missense and splice variants when performing kernel-based association tests (Supplementary Fig. 7). However, a large fraction of these additional associations (31% for splice variants and 48% for missense variants) could also be identified by gene-based variant collapsing for which the sLRT and score test gave almost identical results.

Nevertheless, we found the majority of the remaining additional associations to be plausible and/or previously reported in other association studies and therefore used the sLRT throughout our analysis, except for pLOF variants, where we only performed a gene-based variant collapsing test.

While the score test is the locally most powerful test (i.e., for alternatives that are close to the null hypothesis\(^5\)), our empirical results suggest that the restricted LRT finds more associations. Based on simulations, ref. 11 found that the LRT has higher power if variant effect sizes are large, which is true for many rare variants observed in exome sequencing studies.
Discussion

In our analysis, we combined gene-based variant collapsing and kernel-based tests under a common framework and performed functionally informed gene-based tests for rare variants with 30 biomarkers.

Overall, our approach was successful at identifying disease genes without explicitly using disease diagnoses themselves, even for recessive diseases (e.g., G6PC and glycogen storage disease la^15 or ABCA1 and Tangier disease^69), or diseases with mixed inheritance patterns, while keeping the number of tests low compared to phenotype-wide association studies.

While some of the changes in biomarker levels we detected might be subclinical, they could interfere with the diagnosis of common conditions which rely on biomarkers. To prevent misdiagnoses and enable preventative care, our results could aid the design of targeted sequencing panels that focus on the genes with the highest impacts. For example, we found 8% of the participants to harbor at least one protein LOF variant in any of the significant loci for that variant category. In other words, it is fairly common to have at least one uncommon LOF variant with potential effects on biomarker levels. Genotyping the PIEZO1-L2277M variant in individuals with South Asian ancestry could improve diagnostics in that population, especially if patients present with symptoms typical of dehydrated stomatocytosis, e.g., hemolysis or hyperferritinemia^41.

One major contribution of our study was the design and successful application of kernel-based tests that incorporate quantitative functional variant effect predictions for large exome sequencing data. A previous study had tried to apply kernel-based score tests using SKAT^7 on the 50K WES release, but concluded that results were difficult to reproduce^1. In contrast to their approach, we did not re-weigh variants according to allele frequencies. Furthermore, we showed that a computationally efficient combination of the restricted LRT and score test has potentially higher power than the score test alone (possibly due to the large effect sizes) and identified more associations than gene-based variant collapsing tests.

Ancestry-based variant pruning was necessary to prevent inflation of test statistics for certain biomarkers. This approach worked for us in practice, but could lose power if causal variants are discarded. Future studies could focus on integrating the methods we propose with more sophisticated ways to account for confounding that allow for larger allele frequency differences between individuals of different genetic ancestry^77,29.

When comparing gene-based collapsing and kernel-based tests for missense variants, we found kernel-based tests to have advantages in the presence of gain of function variants (PIEZO1, ABCA1, and JAK2), where they identified plausible causal associations missed by gene-based collapsing tests. These genes likely are examples of a low fraction of causal variants, a regime in which kernel-based tests are statistically more powerful than gene-based collapsing.

While we found a large overlap between our associations and those found in other studies^1, 14, 29, the differences highlight the sensitivity of gene-based tests to qualifying criteria for rare variants (i.e., allele frequencies or variant impact predictions), which can make them harder to reproduce (Supplementary Data 4). By making our analysis pipeline public, we hope to increase reproducibility and enable others to explore different qualifying criteria more easily.

We demonstrated how local collapsing of missense variants by amino acid position aids interpretation and causal reasoning in the presence of previously validated variants. Local collapsing was directly built into the kernel-based tests we performed for missense variants, where it affected 20% of variants, a number which will increase with larger datasets.

We explored the use of deep learning-derived variant effect predictions for splicing and the binding of RBPs. The restriction to exonic regions meant we only observed a fraction of the variants potentially acting through these mechanisms. Associations found by incorporating splice predictions largely overlapped with those identified with pLOF variants (which included simple splice donor/acceptor variants). While we found some associations exclusively with splice predictions, these were mostly due to single variants and would need further validation (e.g., SLC9A5). Similar reasoning holds for the associations found with predictions for RBP-binding.

We anticipate that deep learning-based predictions will become more valuable for non-coding regions in whole-genome sequencing studies, for which the approaches we developed will also be applicable. Deep learning-derived functional annotations have been considered in other studies in the context of association testing. Proposed methods include signed LD-score regression^79, or the association tests presented in DeepWAS^80. However, these methods have not been designed for very rare variants.

In future studies, methods like AlphaFold^81 could allow specific testing of effects on protein folding. Methods that allow predicting residue-residue interactions within proteins could enable the mostly unsupervised identification of protein domains and their separate testing^2. The methodological advances and practices in this association study also apply to those situations and serve as potential baselines for functionally informed kernel-based association tests with rare variants.

Methods

Ethics statement

UK Biobank protocols are overseen by the UK Biobank Ethics Advisory Committee (EAC). Informed consent was obtained for all participants. Participants that revoked consent were removed from the analysis. The original approval for the UK Biobank was granted in 2011 by the National Research Ethics Service (NRES) Committee North West - Haydock. The approval was renewed in 2016 and 2021 by the Health Research Authority, North West - Haydock Research Ethics Committee. This research has been conducted using the UK Biobank resource under application number 40302.

UK biobank data processing

All 30 blood biochemistry biomarkers (category 17518) from the UK Biobank were quantile-transformed to match a normal distribution with mean 0 and unit standard deviation using scikit-learn (v0.22.2)^2. For testosterone, which showed a clear bimodal distribution based on sex, quantile transformation was performed separately for both sexes. We performed ancestry scoring as described in ref. 74 based on the 1000 Genomes super populations^7, which was used to prune variants and select participants with similar genetic ancestry.

Sex, BMI, age at recruitment, smoking status, genetic principal components, and continuous ancestry predictions were used as covariates (Supplementary Data 2). Smoking status (never, previous, current) was encoded in three separate binary variables. Participants with any missing covariates were excluded. We used the ukb_gen_samples_to_remove function of the ukbtools R-package to remove closely related individuals, keeping only one representative of groups that are related to the 3rd degree or less. After removing 6,293 related individuals and restricting to those with no missing covariates, 191,971 participants remained. This sample was 55% female (45% male) and the average age at recruitment was 56.5 years (σ = 8). Furthermore, the average BMI was 27.37 (σ = 4.76) and our subset contained 18,529 current and 66,988 previous smokers.

In our analysis, we made use of the PLINK-formatted exome sequencing genotype data. The final results presented in this manuscript were derived from the 200k WES release produced by the QCFE pipeline^71. The UK Biobank pipeline already implements quality filters^37. Additionally, we removed all variants that violated the Hardy–Weinberg equilibrium (HWE) assumption (HWE exact test p
value below the threshold of $10^{-5}$) and variants genotyped in less than 90% of participants.

We calculated minor allele frequencies within all unrelated participants with complete covariates (see above), and excluded variants with a study-wide allele frequency above 0.1%. In the analysis including all ancestries, we additionally performed ancestry-based pruning to remove variants with large allele frequency differences between ancestries. This lead to the exclusion of 1,033,382 variants. We found this step to be critical for preventing test statistic inflation for kernel-based tests with certain phenotypes. We did not analyze variants on sex chromosomes.

In the all-ancestry analysis 15,701,695 variants passed these filters, of which 45.87% were singletons. 12,793,493 were considered for the EUR ancestry analysis (42.2% singletons). We directly use UK Biobank variant identifiers (which include chromosome and 1-based hg38 positions) to name variants in order to facilitate comparisons.

**Variant effect prediction and annotation**

**Protein loss of function and missense.** We predicted effects for all genetic variants that passed basic filtering using the Ensembl Variant Effect Predictor (VEP, v101; cache version 97), including scores from Polyphen-218 (v2.2.2) and SIFT19 (v5.2.2). All variants marked as splice_acceptor_variant, splice_donor_variant, frameshift_variant, stop_gained, stop_lost, or start_lost were considered protein loss of function (pLOF) variants as in ref. 13. We further annotated missense variants by calculating impact scores (averages between deleterious-probabilities given by PolyPhen-2 and SIFT), which were used to filter and weigh variants in the association tests. Specifically, Missense variants were included if their impact score was at least 0.8 or if they affected amino acid positions for which another variant with an impact score of at least 0.8 was observed.

**Splicing.** We retrieved published pre-computed variant effect predictions produced by the SpliceAI deep learning model20 for single nucleotide polymorphisms. SpliceAI predicts the consequences of genetic variants for nearby splice sites, specifically splice donor loss/gain or splice acceptor loss/gain. We used the splice-site-proximal masked delta scores (v1.3). In the masked files, scores corresponding to the strengthening of annotated splice sites and weakening of non-annotated splice sites are set to 0, as these are generally less pathogenic. We included splice variants in the association tests if at least one of the four SpliceAI delta scores was greater or equal to 0.1. The maxima over the different delta scores for every variant were used to weigh variants in the association tests (details below).

**RBP-binding.** We predicted the effects of all genetic variants on the binding of 6 RNA-binding proteins (RBPs) using a modified version of the DeepRiPe deep neural network25 in which predictions are purely sequence-based (implemented in keras with tensor flow backend, see Data availability statement). We predicted the differences in binding by subtracting the predictions for the reference alleles from those for the alternative allele25, and used these variant effect predictions to filter and weigh variants during the association tests (details below). Variants were included into the association tests if at least one predicted effect on any of the RBPs had an absolute value greater or equal to 0.25.

**Ancestry scoring and ancestry-based variant pruning**

We used GenoPred74 to perform ancestry scoring of all UK Biobank participants. GenoPred uses an elastic net model based on the first 100 genetic principal components of the 1000 Genomes genetic data and super population assignments75 to predict the genetic ancestry of individuals.

In the analysis, including all ancestries, we performed ancestry-based variant pruning, as follows. We limited the analysis to participants with complete covariates and to variants with a study-wide MAF below 0.1% within those individuals. We then defined groups of individuals based on the ancestry prediction model. An individual was assigned to one of the five ancestry groups defined in the 1000 Genomes reference if the predicted probability for that ancestry was greater than or equal to 0.5. 182,288 participants were identified as having predominantly European ancestry (EUR), 4302 South Asian ancestry (SAS), 3775 African ancestry (AFR), 1126 East Asian ancestry (EAS), and 308 admixed American ancestry (AMR). About 172 individuals could not be placed in any of these groups, as all probabilities were below 0.5. These predictions were used to group individuals with similar genetic ancestry according to the 1000 Genomes and do not reflect ethnicity. We then performed two-sided Fisher’s exact tests to identify variants with large deviations from the study-wide EUR allele frequency in any of the other super populations and excluded variants with $p < 10^{-5}$ from the analysis. Variants selectively missing in any of the super populations were excluded.

The predictions from the ancestry prediction model were also used to define the group of participants which were used for the EUR-only analysis, where we applied a more stringent cutoff of $Pr(\text{EUR}) > 0.995$.

**Statistical models and tests**

Let $N(\mu; \Sigma)$ denote a multivariate Normal distribution with means $\mu$ and a variance-covariance matrix $\Sigma$. We wish to jointly test the association of $m$ genetic variants with a quantitative trait $y$ for a sample of $N$ observations (i.e., participants) while controlling for $q$ covariates. Within the linear mixed model framework, $y$ can be modeled as follows36,8:

$$y \sim N(\text{X}\alpha; \sigma^2_1 \text{I}_N + \sigma^2_2 \text{K}_N),$$

where $X$ is the $N \times q$ covariate design matrix (fixed effect) and $\alpha$ is the vector of fixed-effect parameters, which together determine the mean values of $y$. The variance-covariance matrix of $\mathbf{y}$ is composed of the independently distributed residual variance ($\mathbf{I}_N$ scaled by $\sigma^2_2$) and the kernel-matrix $\mathbf{K}_N$ (scaled by $\sigma^2_2$), which captures the genetic similarity between individuals. $\mathbf{K}_N$ is a function of the $N \times m$ mean-centered minor allele counts $\mathbf{G}$ (random effect) of the genetic variants we wish to test.

Any valid variance-covariance matrix can be substituted for $\mathbf{K}_N$. In order to use efficient algorithms for estimating the parameters $\sigma^2_2$ and $\sigma^2_2$ and performing association tests, we require $\mathbf{K}_N$ to be factored as a quadratic form38:

$$\mathbf{K}_N = \phi(\mathbf{G})(\phi(\mathbf{G})^T),$$

where the function $\phi$ transforms $\mathbf{G}$ into intermediate variables before performing the test. Finding an appropriate function $\phi$ depends on the underlying biological assumptions and the available prior information. Gene-based variant collapsing approaches are a special case, in which the function $\phi$ returns an $N \times 1$ vector (a single variable) as output. Therefore kernel-based tests and variant collapsing methods can be treated under the same statistical framework. In our analysis, $\phi$ is a function that transforms $\mathbf{G}$ taking variant effect predictions and, for missense and RBP-variants, variant positions into account.

Regardless of the choice of kernel (and hence $\phi$) the statistical test is defined by the null hypothesis $H_0: \sigma^2_2 = 0$, and the alternative hypothesis $H_1: \sigma^2_2 > 0$ (i.e., a one-sided test). Both a score test and likelihood-ratio test (LRT) have been described for this application. While the score test is often chosen in statistical genetics applications due to its speed and software availability, the LRT has been shown to have higher power when effect sizes are large but is computationally more demanding8,11.
In order to avoid computing the LRT for all genes but still profit from a potentially higher power, we performed score tests genome-wide and only performed the restricted LRT if score tests (within the specific variant category) reached nominal significance, an approach which we call the score-LRT (sLRT, see sections below). The sLRT returns the p value for the score test if nominal significance was not reached, otherwise it returns the p value for the likelihood-ratio test.

We sampled RLRT test statistics using fast exact algorithms described in ref. 80, and fit parametric null distributions to the pooled test statistics across genes in order to calculate p values41. Null distribution parameters are available in Supplementary Data 1. We did this separately for different variant-effect and test-types. This method gave highly similar p values to using gene-specific null distributions (Supplementary Figs. 9–12), but is faster as it requires fewer test statistics to be simulated per gene and fewer distributions to be fit. Furthermore, using the pooled distribution does not change the bound of the FWER compared to using gene-specific null distributions to calculate p values (see sections below).

We applied the statistical framework above to perform both gene-based variants collapsing tests and kernel-based association tests, corresponding to different functions p as detailed below. Additionally, for splice and missense variants, tests using only those variant categories and tests combining these variant categories with pLOF variants were integrated into single tests using the Cauchy combination test28. We adjust p values for the total number of 3,091,910 tests in the all-ancestry analysis using Bonferroni correction (FWER ≤ 0.05), which lead to a cutoff of $1.6171 \times 10^{-6}$.

**Variant weight calculation**

All association tests we performed incorporated variant weights, which were derived from variant effect predictions. All variant weights we used are numbers between 0 and 1. For protein LOF variants, all weights were set to 1. For missense variants, we calculated the weights as follows:

$$w_i = \frac{(1 - s_i,\text{SIFT}) + s_i,\text{Polyphen}}{2}$$

(3)

where $w_i$ is the weight for variant $i$, $s_i,\text{SIFT}$ and $s_i,\text{Polyphen}$ denotes the SIFT and Polyphen scores for variant $i$, respectively (potentially averaged across different transcript variants). This score can be interpreted as the average of the predicted probability of the variant being deleterious predicted by the two methods.

For splice variants, the weight $w_i$ for specific variant $i$, was set to the maximum of its four SpliceAI delta scores.

Regarding the predictions for the binding of RBPs, we proceeded as follows: While the experiments for the RBP QKI had been replicated in three cell lines, those for the other 5 RBPs had only been performed in a single cell line. As every replicate is a separate model output, this resulted in a total of eight predictions for each genetic variant. We predicted the binding probability of each RBP to sequences centered on the major and minor alleles, while applying 4 bp shifts around the center. We averaged four predictions across these small shifts to reduce variability. Finally, we calculated variant effect predictions $v_i$ for each variant $i$ and RBP-replicate $j$ by subtracting the prediction for the reference allele ($p_{i,\text{ref}}$) from the prediction for the alternative allele ($p_{i,\text{alt}}$):

$$v_{ij} = p_{ij,\text{alt}} - p_{ij,\text{ref}}$$

(4)

These variant effect predictions are numbers between –1 and 1, where the sign denotes a gain of binding (+) or a loss of binding (–). They were used to determine variant weights and variant similarities during association testing (see below), where we set the weight $w_i$ of variant $i$ to the largest absolute value of $v_i$.

**Gene-based variant collapsing tests**

In gene-based variant collapsing, all qualifying variants overlapping a specific gene are collapsed into a single variable prior to association testing, i.e., $\phi(G)$ in (2) returns an $N \times 1$-vector. We modified the approach in ref. 13 by incorporating variant effect predictions as weights. Within a specific gene, any participant could carry 0 or more qualifying variants, where each variant $i$ has a weight $w_i$ (derived from variant effect prediction, see above). Specifically, the collapsed score is the largest weight of any of the variants observed for a specific participant, or 0 if no qualifying variants were observed for that participant. This score makes three assumptions: additive effects are negligible (or unrealistic), variants with larger weights dominate over those with smaller weights and all variants affect the quantitative trait in the same direction.

**Functionally informed kernel-based tests**

The kernels we used in this analysis follow the general form:

$$K_F = GWSWG^T.$$

(5)

where $W$ is an $m \times m$ diagonal matrix containing the square roots of variant weights on the diagonal and the $m \times m$ matrix $S$ captures similarities between the genetic variants, $G$ is the $n \times m$ matrix of mean-centered minor allele counts of the qualifying variants within the gene to be tested, $S$ can be interpreted as the variance-covariance matrix of regression coefficients of intermediate variables $GW$. We use $W$ and $S$ to incorporate variant effect predictions (and other variant annotations) into the association tests.

While a shared regression coefficient ($S = I_{m \times m}$) might be a poor assumption in some cases, so can completely independent regression coefficients ($S = I_n$). The former, when substituted into (5), has been referred to as the weighted counting burden test, whereas the latter is commonly called the weighted linear kernel42. In our analysis, we define $S$ based on available prior knowledge and type of variant effect prediction.

**Missense.** For the analysis of missense variants, we introduce the locally collapsing kernel. Local collapsing aggregates groups of variants into single variables before performing the association test. “Local” refers to the fact that the groups are defined by the proximity of variants in the DNA-, RNA-, or amino acid sequence. We grouped variants if they affect the same exact amino acid position of a specific gene. Once the groups are defined, local collapsing can be expressed as a matrix multiplication: $S = CC^T$ and the kernel (5) becomes:

$$K_F = GWCC^TW^T$$

(6)

Here $C$ is the $m$-variants by $g$-groups collapsing matrix. Therefore $GWC$ is the $n \times g$ weighted locally collapsed genotype matrix (where the columns now represent amino acid positions instead of single genetic variants). The columns of $C$ define the group assignments and directionality of variant effects. For every variant $i$ from 1 to $m$ with (potentially signed) variant effect $v_i$ and group $j$ from 1 to $g$, $c_{ij} = \text{sgn} v_i$ if variant $i$ belongs to group $j$, else $c_{ij} = 0$. In our case, variant effect predictions were unsigned (all positive). The assumptions of the locally collapsing kernel are that variants within groups share a common regression coefficient once they have been scaled by and aligned with the direction of their variant effect predictions.

**RBP-binding.** Sometimes there are no clearly defined groups of variants or multiple (potentially directional) variant effect predictions need to be accounted for at once, and therefore, variants can’t easily be collapsed. Given what we know about the location of variants and their predicted effects, we might still make assumptions about $S$. As long as $S$ is positive definite, we can find a suitable square root $L$ so that $LL^T = S$ using the Cholesky decomposition. In the association tests involving directional predictions for the binding of RNA-binding proteins we calculated $S$ by...
forming the element-wise product of two $m \times m$ matrices:

$$S = LL^T - Q \circ R$$

(7)

Where $Q$ captures the similarity of variants based on their variant effect predictions and $R$ captures the similarity of variants based on their positions. Specifically, let $v_i$ be the vector of variant effect predictions for variant $i$. Then the element $q_{ij}$ of $Q$ is the cosine similarity between $v_i$ and $v_j$. We chose to model the position-dependent similarity with a Gaussian kernel. If $x_i$ is the chromosomal position of variant $i$, $r_{ij} = \exp(-\gamma(x_i - x_j)^2)$, where we set $\gamma = \frac{\text{log} 0.5}{50}$. At this value of $\gamma$ two variants that are 50 bp apart have a similarity of 0.5, which decays rapidly as the distance increases. As both $Q$ and $R$ are positive definite matrices, so is $Q \circ R$. This kernel makes the assumption that variants that are in close proximity and have aligned variant effect predictions should affect the phenotype in the same direction.

Score- and likelihood-ratio test implementation

In order to use efficient algorithms for estimating the parameters $\sigma^2_S$ and $\sigma^2_Q$ in (1) and performing association tests, we require $K_g$ to be factored as a quadratic form as shown in (2)\(^8\). The function $\phi$ in (2) transforms the genotype matrix $G$ into intermediate variables before performing the test.

The test statistic of the score test approximates the change of the log-likelihood of a model when including $K_g$ over the null model, which does not include $K_g$ ($\sigma^2_Q = 0$)\(^9\). We calculated test statistics using fast algorithms described in ref.\(^9\) and applied Davies’ method for the calculation of $p$ values\(^8\) with accuracy of $10^{-7}$ and $10^{-10}$ iterations. Where Davies’ method returned $p$ values of 0, or in the rare cases where Davies’ method returned invalid (negative) $p$ values, we used saddle point approximation instead\(^8\).

The test statistic of the restricted likelihood-ratio test is twice the difference between the log restricted likelihood of the alternative model and the null model\(^9\). We used FaST-LMM’s LMM class\(^8\) to fit the null and alternative models using restricted maximum likelihood and then calculated test statistics. To generate a null distribution we sampled 100 test statistics for every LR test, using our own port of RLRsim\(^8\) in Python (as part of the peak package, see Code availability statement). Finally, we fit a parametric null distribution $\pi_{\chi^2} + (1 - \pi)\pi_{\chi^2}^2$ with free parameters $\pi$, $a$, and $d$ to the pooled simulated test statistics using log-quantile regression on the 10% of largest test statistics\(^9\), and used this distribution to calculate $p$ values as described in ref.\(^9\) (Supplementary Data 1). We used separate null distributions for all variant-type to test-type and phenotype combinations (see details below).

We compared this approach to using gene-specific null distributions (i.e., fitting a separate null distribution for every test and gene, similar to the method described in ref.\(^12\)), and found that they produced highly similar results (Supplementary Figs. 9–11).

To this end, we performed two analyses: First, we looked at genes close to or below the genome-wide significance threshold. We compared the Pearson correlation of the log10 $p$ values derived from the genome-wide pooled or gene-specific null distributions for genes with association $p$ values below 10\(^{-8}\) in any of the initially performed tests. We did this separately for the different variant categories and test types based on 250,000 gene-specific samples from the null distribution. Second, for every phenotype and variant category, we randomly sampled 100 genes with $p$ values above 10\(^{-5}\) (in any of the previously performed tests for that variant category) and cumulative minor allele counts of at least 5, and repeated the comparison (again based on 250,000 samples per test).

For associations close to or below the significance threshold, the average $r^2$ was 0.999 for kernel-based tests and 0.999 for gbvc tests. For non-significant associations, average $r^2$ values were 0.9897 for kernel-based tests, and 0.999 for gbvc tests. We conclude that the pooled null distribution is a good approximation of the individual gene-level null distributions. An example illustrating this approach is shown in Supplementary Fig. 12.

Gene-based testing procedure summary

We performed gene-based tests for all protein-coding genes in the Ensembl 97 release. For all pLOF variants we performed gene-based variant collapsing using the score test genome-wide.

For missense variants, we performed both weighted gene-based variant collapsing and kernel-based association tests using the sLRT. For the kernel-based tests with missense variants, we designed a kernel that collapses variants by amino acid position (local collapsing) and weights them by their impact score. Additionally, in cases where either missense-variant score test used in the sLRT was nominally significant ($p < 0.1$), we combined missense and protein LOF variants for joint tests. For these joint tests, we investigated both the use of joint weighted gene-based variant collapsing and a kernel-based test that combines collapsing of pLOF variants with local collapsing of missense variants by concatenation (detailed description below). The $p$ values of the combined tests were integrated using the Cauchy combination method\(^8\) (individual $p$ values are reported in Supplementary Data 1).

For predicted splice variants, we followed the same strategy as for missense variants, however, we used the weighted linear kernel\(^7\) without local collapsing instead. Finally, in the association tests, including variants predicted to change the binding of RBPs, we only performed kernel-based association tests using the sLRT. For this purpose, we designed a kernel that can take into account both variant positions and the direction of variant effects (as described above).

Because some of the genes in the Ensembl 97 release share exons, we encountered cases in which these genes shared associations caused by the same variants. We do not report these as distinct genes in the main text or abstract, but include the full list of 212 associations in Supplementary Data 1.

sLRT detailed description

Missense. For missense variants, we iterated over all genes and performed score tests using gene-based variant collapsing and kernel-based tests (locally collapsing kernel), i.e., the diagonal elements $w_i$ of $W$ in (5) contained the square roots of the impact scores of variants. If either score test $p$ value was nominally significant ($p < 0.1$) we also performed the following steps: (1) Calculation of restricted likelihood-ratio test statistics (sLRT), (2) gene-based variant collapsing combining both missense and loss of function variants in a joint test, (3) concatenation of the collapsed pLOF variable to the locally collapsed weighted matrix of missense variant minor allele counts (GWC, Equation (6)) and a joint kernel-based RLRT. For all likelihood-ratio tests, we simulate 100 gene-specific test statistics from the null distribution each.

Once all genes were processed for a specific phenotype, we fit separate null distributions to the pooled simulated test statistics for each of the four groups of likelihood-ratio tests: collapsed missense variants (gbvc), jointly collapsed pLOF and missense variants (gbvc), locally collapsed missense variants (kernel-based), locally collapsed missense variants concatenated with collapsed pLOF variants (kernel-based). $p$ values were then calculated for all tests based on those distributions. Finally, the $p$ values for the two kernel-based tests, and the two gbvc tests were combined using the Cauchy combination test, resulting in a single kernel-based and a single gbvc test per gene.

We used the locally collapsing kernel in the kernel-based association tests for missense variants as it had given more unique associations and overall slightly lower $p$ values for the most significant genes in initial experiments on the 50k WES release, and was more interpretable compared to other approaches.
Splicing. For splice variants, we performed score tests using gene-based variant collapsing and the linear weighted kernel for all genes. Again, if either of the two score tests were nominally significant ($p < 0.1$), we performed likelihood-ratio tests (lSRT). As we did for missense variants, we then also performed combined association tests with protein loss of function variants using both gene-based variant collapsing and a kernel-based LRT. For the kernel-based test, we concatenated the protein LOF indicator variable to the matrix of weighted minor allele counts $GW$ (Equation (5), where $S = 1_{m_l}$). In the cases where a variant was annotated both as a splice variant and pLOF variant, we treated it as a pLOF variant in the joint tests. As we did for missense variants, after calculating $p$ values using four separate null distributions for every phenotype, we combined the two kernel-based tests and the two gene-based collapsing tests into single tests using the Cauchy combination test.

RBP-binding. For variants predicted to alter the binding of RBPs we only performed kernel-based association tests using the kernel in (5), where we used the largest absolute value of the variant effect predictions as the weights and calculated $S$ as described above in (7). We iterated over all genes and performed gene-based score tests. Because the DeepRiPe variant effect predictions are strand-specific, we did this independently for genes on the forward or reverse strands. If the score test for a specific gene was nominally significant ($p < 0.1$), we performed the likelihood-ratio test for that gene (lSRT). If the variants tested also included variants annotated as protein loss of function variants, we removed them and repeated the tests to avoid false positives.

Conditional association tests

For significant associations after multiple testing correction, we performed conditional association tests. For every significant gene-biomarker association, we identified single variants significantly associated with the same biomarker within ± 500kb of the gene start position, based on the summary statistics provided by ref. 23. We then conditioned on the single variant with the lowest $p$ value (if any) by incorporating it as a covariate in a gene-specific null model (in case of ties, the closest variant to the gene start position was chosen). We then fit the alternative model, calculated the model likelihoods and LRT test statistics, and simulated 250,000 gene-specific LRT test statistics for every alternative model (i.e., combinations of variant- and test-types). We fit parametric null distributions to these test statistics using the 10% of largest test statistics (as described above), and calculated $p$ values based on these null distributions. We then combined the $p$ values using the CCT (if combined tests with pLOF variants were performed). Conditional $p$ values and the variants that were conditioned are reported in Supplementary Data 1.

Cross-referencing against GWAS databases

We queried the NHGRI-EBI GWAS Catalog$^{24,27}$ and PhenoScanner$^{26,27}$ in order to see if single variants within the genes we found significantly associated with a specific biomarker had already been reported to be associated with that biomarker. For each gene, we submitted region queries using the gene boundaries with the gwasrapidd85 (v0.99.11) and phenoscanner (v1.0) R-packages. For PhenoScanner, we set the $p$ value threshold to 10$^{-7}$. Matching our results to those contained in these databases required us to define a mapping of UK Biobank biomarkers to the Experimental Factor Ontology (EFO) terms used in those databases. This mapping is provided in Supplementary Data 2. Additionally, as EFO terms for PhenoScanner were not always defined, we performed the following matching: “Apolipoprotein B” (UKB phenotype) to “APOB apolipoprotein B” (PhenoScanner trait), “Cystatin C” to PhenoScanner traits “log eGFR cystatin C”, “Serum cystatin c estimated glomerular filtration rate eGFR”, and “Cystatin C in serum”, and “Urea” to “Renal function related traits urea”.

PIEZO1-L2277M association tests

We used the ancestry classifications described above to define a group of individuals of SAS ancestry, and one of extended EUR ancestry (both using a cutoff of >0.5 in the ancestry classification model). This is a less stringent cutoff than that used in the EUR-analysis for all biomarkers and increased the number of observed carriers in the EUR-ancestry group from 5 to 21, all heterozygous. We used the same covariates as in the all-ancestry analysis.

Genotypes were derived from exome sequencing and we performed association tests using the score test with ancestry-specific null-models. For the association tests in the SAS group, we performed conditional tests by conditioning the test statistic on the genotypes of the 16:88784993:C:G variant, which were also derived from exome sequencing.

FWER control for the pooled null distribution

For the LRT we derive $p$ values from pooled gene-specific test statistics under the null hypothesis and use Bonferroni correction on these $p$ values to bound the FWER. Below we show why this approach does not change the bound of the FWER compared to using gene-specific null distributions to calculate $p$ values, assuming the pooled distribution is well estimated.

Let $i$ be a sample from a random variable. For $i$ from 1 to $n$, $i$ corresponds to the test statistics for gene $i$ under the null hypothesis. For a specific value of the test statistic $x$, the distribution function $F_i$ returns the $p$ value $p_i$:

$$F_i(x) = Pr(I_i \leq x) = p_i$$

Let $M$ be the random variable arising from a uniform mixture of all $I_i$, i.e., $M = \bigcup_{i=1}^{n} I_i$, with corresponding distribution function:

$$F_M(x) = Pr(M \leq x) = \sum_{i=1}^{n} \frac{F_i(x)}{n} \frac{Pr(I_i \leq x)}{n} = \frac{\sum_{i=1}^{n} p_i}{n} = \frac{\sum_{i=1}^{n} A_i}{n}$$

I.e., when the mixture components are sampled to the same proportions, the $p$ value of the mixture distribution $p_m$ is the average $p$ value of the mixture components $p_i$. In this setting, empirically choosing a single cutoff $x_m$ corresponding to a significance cutoff $\alpha$ based on the mixture distribution controls the FWER at the same level as setting gene-specific cutoffs $x_i$ such that all $\alpha_i = \alpha$ (the commonly applied approach).

The bound for family-wise error rate across all genes 1 to $n$ is given by Boole’s inequality as used in the Bonferroni correction:

$$FWER = \Pr\left(\bigcup_{i=1}^{n} \left\{ p_i \leq \frac{\alpha}{n} \right\} \right) \leq \sum_{i=1}^{n} \Pr\left( p_i \leq \frac{\alpha}{n} \right) = \sum_{i=1}^{n} \frac{\alpha_i}{n} = \alpha$$

Notably, tests can also be performed at different significance levels $\frac{\alpha}{n}$. If the average gene-specific alpha ($\alpha_i$) is exactly $\alpha$, the bound for the FWER remains unchanged:

$$\sum_{i=1}^{n} \Pr\left( p_i \leq \frac{\alpha_i}{n} \right) = \frac{\sum_{i=1}^{n} \alpha_i}{n} = \frac{\sum_{i=1}^{n} \alpha}{n} = \frac{n}{n} \alpha = \alpha$$

This property has been used in the context of weighted Bonferroni correction, and related proofs apply$^{28}$. Based on the formulae above, any cutoff $\alpha_m$ based on the mixture distribution corresponds to the average theoretical cutoff of the mixture components $\alpha_m$. It follows that

$$\sum_{i=1}^{n} \Pr\left( p_m \leq \frac{\alpha_m}{n} \right) = \frac{\sum_{i=1}^{n} \alpha_m}{n} = \frac{\sum_{i=1}^{n} \alpha_i}{n} = \frac{n}{n} \alpha = \alpha$$

The FWER is controlled at the same level as if we had performed tests using the gene-specific null distributions and set all $\alpha_i = \alpha$, or in
fact, any other values of $\frac{p^*}{n}$ that sum up to $\alpha^{\frac{1}{2}}$. Based on our experiments comparing $p$ values derived from the gene-specific null distributions to those derived from the mixture distribution, we show that $p_{a} \sim p_{m}$, and therefore $a_{x} = a_{m}$.

Additionally, we prevent false positives due to differences in $p_{a}$ and $p_{m}$ by performing gene-specific conditional tests for the genes which reach genome-wide significance using the mixture distribution. This means our approach may lose power; we can miss genes that would be significant using gene-specific null distributions, but not significant based on the mixture distribution.

Software

Here we list software not otherwise mentioned in the manuscript. For the full list including version numbers consider the Reporting Summary. Our functional annotation and association testing pipeline (faatpipe) uses bcftools97, bedtools88, Plink89, samtools90, vcftools91, biopython92, pybedtools93, pyranges94, pysam (https://github.com/pysam-developers/pysam), and pysnptools (https://github.com/HealthML/pysnptools) to handle genomic ranges and genotype data. Figures were produced using ggplot295, gplots96, matplotlib97, seaborn98, and matplotlib_venn (https://github.com/HealthML/matplotlib_venn).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

Variant effect predictions for all variants in the 200k exome sequencing release are made available on github (https://github.com/HealthML/ukb-200k-wes-vep), v0.0.0, doi.org/10.5281/zenodo.6912352).

The weights for the DeepRiPe model used to predict the effects of variants on RBP-binding are available at https://github.com/HealthML/faatpipe/tree/master/data/deepripe_models. SpliceAI variant effect predictions are publicly made available by Illumina at https://basespace.illumina.com/cdsSPW8inhzA/ZR.

The Online Mendelian Inheritance in Man (OMIM®) database is publicly accessible through https://omim.org. The ClinVar database is publicly accessible through https://www.ncbi.nlm.nih.gov/clinvar/. The NHGRI-EBI Catalog of human genome-wide association studies (GWAS catalog) is publicly accessible through https://www.ebi.ac.uk/gwas/. Phenoscanner, a database of human genotype-phenotype associations, is publicly available through http://www.phenoscanner.medschl.cam.ac.uk/. The 1000 Genomes phase 3 genotypes are publicly available at https://ftp1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20140708_previous_phase3/v5.vcf.s.

The genetic, phenotype, and covariate data are protected and are only available to researchers that have valid and approved research applications for these data within the UK Biobank (www.ukbiobank.ac.uk/).

Code availability

A snakemake pipeline that allows reproducing results from this study is available on github (https://github.com/HealthML/faatpipe, v0.1.0, doi.org/10.5281/zenodo.6912198).

The implementation of statistical tests (score test, LRRT), including the python port of RLRsim87 is available on github (https://github.com/HealthML/seak, v0.4.3, doi.org/10.5281/zenodo.6912202).

References

1. Sudlow, C. et al. Uk biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12, e1001779 (2015).
2. Buniello, A. et al. The nhgr-ebi gwas catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47, D1005–D1012 (2019).
3. Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747–753 (2009).
4. Hernandez, R. D. et al. Ultrarare variants drive substantial cis heritability of human gene expression. Nat. Genet. 51, 1349–1355 (2019).
5. Zhu, Q. et al. A genome-wide comparison of the functional properties of rare and common genetic variants in humans. Am. J. Hum. Genet. 88, 458–468 (2011).
6. Li, B. & Leal, S. M. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83, 311–321 (2008).
7. Lee, S., Abecasis, G. R., Boehnke, M. & Lin, X. Rare-variant association analysis: study designs and statistical tests. Am. J. Hum. Genet. 95, 5–23 (2014).
8. Wu, M. C. et al. Rare-variant association testing for sequencing data with the sequence kernel association test. Am. J. Hum. Genet. 89, 82–93 (2011).
9. Listgarten, J. et al. A powerful and efficient set test for genetic markers that handles confounders. Bioinformatics 29, 1526–1533 (2013).
10. Poyssil, G. et al. Rare-variant collapsing analyses for complex traits: guidelines and applications. Nat. Rev. Genet. 20, 747–759 (2019).
11. Lippert, C. et al. Greater power and computational efficiency for kernel-based association testing of sets of genetic variants. Bioinformatics 30, 3206–3214 (2014).
12. Zhou, J. J., Hu, T., Qiao, D., Cho, M. H. & Zhou, H. Boosting gene mapping power and efficiency with efficient exact variance component tests of single nucleotide polymorphism sets. Genetics 204, 921–931 (2016).
13. Cirulli, E. T. et al. Genome-wide rare variant analysis for thousands of phenotypes in over 70,000 exomes from two cohorts. Nat. Commun. 11, 542 (2020).
14. Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 individuals in the uk biobank. Nature 586, 749–756 (2020).
15. Wang, Q. et al. Rare variant contribution to human disease in 281,104 uk biobank exomes. Nature 597, 527–532 (2021).
16. Backman, J. D. et al. Exome sequencing and analysis of 454,787 uk biobank participants. Nature 599, 626–634 (2021).
17. McLaren, W. et al. The ensemble variant effect predictor. Genome Biol. 17, 1–14 (2016).
18. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting functional effect of human missense mutations using polyphen-2. Curr. Protoc. Hum. Genet. 76, 7–20 (2013).
19. Ng, P. C. & Henikoff, S. Sift: Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812–3814 (2003).
20. Sundaram, L. et al. Predicting the clinical impact of human mutation with deep neural networks. Nat. Genet. 50, 1161–1170 (2018).
21. Szustakowski, J. D. et al. Advancing human genetics research and drug discovery through exome sequencing of the uk biobank. Nat. Genet. 53, 942–948 (2021).
22. Strimbu, K. & Tavel, J. A. What are biomarkers? Curr. Opin. HIV AIDS 5, 463 (2010).
23. Sinnott-Armstrong, N. et al. Genetics of 35 blood and urine biomarkers in the UK biobank. Nat. Genet. 53, 185–194 (2021).
24. Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548 (2019).
25. Ghanbari, M. & Ohler, U. Deep neural networks for interpreting rna-binding protein target preferences. Nat. Rev. Genet. 24, 1001779 (2015).
26. Staley, J. R. et al. Phenoscanner: a database of human genotype-phenotype associations. Bioinformatics 32, 3207–3208 (2016).
27. Kamat, M. A. et al. Phenoscaner v2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics 35, 4851–4853 (2019).
28. Liu, Y. & Xie, J. Cauchy combination test: a powerful test with analytic p value calculation under arbitrary dependency structures. J. Am. Stat. Assoc. 115, 393–402 (2020).
29. Mukthavee, N. et al. Describing human ribonucleoprotein regulatory networks. Nucleic Acids Res. 47, 570–581 (2019).
30. Willnow, T. E. & Christ, A. Endocytic receptor Lrp2/megalin-of holoprosencephaly and renal fanconi syndrome. Pflügers Arch. Eur. J. Physiol. 469, 907–916 (2017).
31. Zhao, Y. et al. Gigyf1 loss of function is associated with clonal mosaicism and adverse metabolic health. Nat. Commun. 12, 1–6 (2021).
32. Deaton, A. M. et al. Gene-level analysis of rare variants in 379,066 whole exome sequences identifies an association of gigyf1 loss of function with type 2 diabetes. Sci. Rep. 11, 1–16 (2021).
33. Jurgens, S. J. et al. Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200,000 individuals in the uk biobank. Nat. Genet. 54, 240–250 (2022).
34. James, C. et al. A unique clonal jak2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144–1148 (2005).
35. Chou, J. Y. & Mans, J. F. The monovalent cation leak in overhydrated stomatocytosis. J. Mol. Biol. 36, 226–229 (2004).
36. Marcil, M. et al. Mutations in the abc1 gene in familial hdl deficiency with defective cholesterol efflux. Lancet 354, 1341–1346 (1999).
37. Sun, Q. et al. Analyses of biomarker traits in diverse uk biobank. J. Intern. Med. 285, 285–292 (2009).
38. Nagao, K., Zhao, Y., Takahashi, K., Kimura, Y. & Ueda, K. Sodium taurocholate-dependent lipid efflux by abca1: effects of w590s mutation on lipid translocation and apolipoprotein ai dissociation. J. Lipid Res. 50, 1105–1115 (2009).
39. Probst, M. C. Development and evaluation of multiplex and high-throughput SNP analysis for the ABCA1 gene. Ph.D. thesis (2004).
40. Enkhmaa, B., Anuuarad, E., Zhang, W., Tran, T. & Berglund, L. Lipoprotein (a): genotype–phenotype relationship and impact on atherogenic risk. Metabol. Syndr. Relat. Disord. 9, 411–419 (2011).
41. Shadrina, A. S. et al. Prioritization of causal genes for coronary artery disease based on cumulative evidence from experimental and in silico studies. Sci. Rep. 10, 1–15 (2020).
42. Sarras, H., Alizadeh Azami, S. & McPherson, J. P. In search of a function for bclaf1. ScientificWorldJournal 10, 1450–1461 (2010).
43. Jostins, L. et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119–124 (2012).
44. Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979–986 (2015).
45. Choi, Y. et al. Causal associations between serum bilirubin levels and decreased stroke risk: a two-sample mendelian randomization study. Arterioscler. Thromb. Vasc. Biol. 40, 437–445 (2020).
46. Lee, J. Y. et al. A genome-wide association study on liver enzymes in korean population. PLoS ONE 15, e0229374 (2020).
47. Lin, X. Variance component testing in generalised linear models with random effects. Biometrika 84, 309–326 (1997).
48. Rust, S. et al. Tangier disease is caused by mutations in the gene encoding atp-binding cassette transporter 1. Nat. Genet. 22, 352–355 (1999).
49. Zhou, W. et al. Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. Nat. Genet. 52, 634–639 (2020).
50. Mbatchou, J. et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. 53, 1097–1103 (2021).
51. Reshef, Y. A. et al. Detecting genome-wide directional effects of transcription factor binding on polygenic disease risk. Nat. Genet. 50, 1483–1493 (2018).
52. Arloth, J. et al. Deepwas: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning. PLoS Comput. Biol. 16, e1007616 (2020).
Senior, A. W. et al. Improved protein structure prediction using potentials from deep learning. Nature 577, 706–710 (2020).

Rives, A. et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc. Natl Acad. Sci. USA 118, e2016239118 (2021).

Pedregosa, F. et al. Scikit-learn: machine learning in python. J. Mach Learn Res. 12, 2825–2830 (2011).

Pain, O. et al. Evaluation of polygenic prediction methodology within a reference-standardized framework. PLoS Genet. 17, e1009021 (2021).

Fairley, S., Lowy-Gallego, E., Perry, E. & Flick, P. The international genome sample resource (igsr) collection of open human genomic variation resources. Nucleic Acids Res. 48, D941–D947 (2020).

Hanscombe, K. B., Coleman, J. R., Traylor, M. & Lewis, C. M. ukbtools: an r package to manage and query uk biobank data. PLoS ONE 14, e0214311 (2019).

Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature 586, 749–756 (2020).

Zhou, J. & Troyanskaya, O. G. Predicting effects of noncoding variants with deep learning–based sequence model. Nat. Methods 12, 931–934 (2015).

Consortium, G. P. et al. A global reference for human genetic variation. Nature 526, 68 (2015).

Scheipl, F., Greven, S. & Kuechenhoff, H. Size and power of tests for a zero random effect variance or polynomial regression in additive and linear mixed models. Comput. Stat. Data Anal. 52, 3283–3298 (2008).

Lee, S., Wu, M. C. & Lin, X. Optimal tests for rare variant effects in sequencing association studies. Biostatistics 13, 762–775 (2012).

Davies, R. B. The distribution of a linear combination of η2 random variables. J. R. Stat. Soc. Ser. C (Appl. Stat.) 29, 323–333 (1980).

Kuonen, D. Miscellanea. saddlepoint approximations for distributions of quadratic forms in normal variables. Biometrika 86, 929–935 (1999).

Lippert, C. et al. Fast linear mixed models for genome-wide association studies. Nat. Methods 8, 833–835 (2011).

Magno, R. & Maia, A.-T. gwasrapidd: an r package to query, download and wrangle gwas catalog data. Bioinformatics 36, 649–650 (2020).

Genovese, C. R., Roeder, K. & Wasserman, L. False discovery control with application number 40502. This research has received funding from the German Federal Ministry of Education and Research (BMBF) in the projects SyReal (project number 01IS1069A) and KI-LAB-ITSE (project number 01IS19066), and the European Commission in the Horizon 2020 project INTERVENE (Grant agreement ID: 101016775).

Author contributions

R.M., S.K., and C.L. conceived and designed the study, R.M., P.R., A.R.J., and S.K. performed initial prototyping, R.M. and P.R. wrote software to perform the statistical tests with guidance from U.O., S.K., and C.L. R.M. wrote the analysis pipeline with guidance from A.R.J., U.O., and C.L. R.M. carried out the statistical analyses with guidance from S.K., U.O., and C.L. M.G. supplied the weights for the DeepRF model and produced attribution maps. P.R. and R.M. queried GWAS databases and compared results with other studies. R.M., M.K., and C.L. contributed to the theoretical arguments regarding FWER control. R.M., P.R., S.K., and C.L. wrote the manuscript. All authors revised the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-32864-2.

Correspondence and requests for materials should be addressed to Christoph Lippert. Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available. Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022